Home » Stocks » Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc. (STSA)

Stock Price: $24.95 USD -0.05 (-0.20%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 433.87M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 17.39M
EPS (ttm) -11.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $24.95
Previous Close $25.00
Change ($) -0.05
Change (%) -0.20%
Day's Open 25.41
Day's Range 24.74 - 25.46
Day's Volume 65,875
52-Week Range 8.61 - 36.11

More Stats

Market Cap 433.87M
Enterprise Value 337.55M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 17.39M
Float 6.98M
EPS (basic) n/a
EPS (diluted) -11.20
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 155,342
Short Ratio 1.58
Short % of Float 2.78%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.14
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 96.32M
Net Cash / Share 5.54
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -27.50%
ROE -71.75%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(34.27% upside)
Current: $24.95
Target: 33.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-28.88-7.52-4.95
Net Income-28.18-7.35-5.17
Shares Outstanding5.861.030.56
Earnings Per Share-4.80-7.15-9.26
Operating Cash Flow-29.64-6.98-4.32
Capital Expenditures-0.55-0.40-0.06
Free Cash Flow-30.19-7.38-4.38
Cash & Equivalents1085.211.66
Total Debt4.934.970.09
Net Cash / Debt1030.241.56
Book Value115-12.13-5.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Satsuma Pharmaceuticals, Inc.
Country United States
Employees 20
CEO John A. Kollins

Stock Information

Ticker Symbol STSA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: STSA
IPO Date September 13, 2019


Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.